PARP Inhibitors Market Growth, Regional Segmentation, and Key Players Forecast to 2024-2031 - AstraZeneca, Pfizer Inc., GSK plc.

The global PARP inhibitors market reached US$ 3.53 billion in 2023 and is expected to reach US$ 6.64 billion by 2031, growing at a CAGR of 8.3% during the forecast period 2024-2031.

PARP Inhibitors Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/parp-inhibitors-market?rk

Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted cancer therapies that prevent DNA repair in cancer cells, leading to cell death. They are particularly effective in treating cancers with BRCA1/2 mutations, such as ovarian, breast, and prostate cancers. By blocking PARP enzymes, these drugs exploit the inability of mutated cells to repair themselves, a concept known as synthetic lethality. FDA-approved PARP inhibitors include olaparib (Lynparza), niraparib (Zejula), and rucaparib (Rubraca). The market for PARP inhibitors is expanding with ongoing research into their combination with immunotherapy and chemotherapy.

List of the Key Players in the PARP Inhibitors Market:

AstraZeneca, Pfizer Inc., GSK plc, Pharmaand GmbH., Globela Pharma, Johnson & Johnson Services, Inc., Merck & Co., Inc., Beacon Pharmaceuticals PLC, and EVEREST among others.

Emerging Players

The emerging players in the global PARP inhibitors market include Artios Pharma, Repare Therapeutics, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and ONO PHARMACEUTICAL CO., LTD

Industry Development:

In July 2024, AstraZeneca announced the DUO-O Phase III trial, which explored the combination of Lynparza (olaparib) and Imfinzi (durvalumab) with chemotherapy and bevacizumab in newly diagnosed patients with advanced high-grade epithelial ovarian cancer who do not have tumor BRCA mutations.

Growth Forecast Projected:

The Global PARP Inhibitors Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global PARP Inhibitors Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/parp-inhibitors-market?rk

Segment Covered in the PARP Inhibitors Market:

By Application: Breast Cancer , Ovarian Cancer, Prostate Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Others

By Distribution Channel: Hospital Pharmacies , Retail Pharmacies, Online Pharmacies

Regional Analysis for PARP Inhibitors Market:

The regional analysis of the PARP Inhibitors Market covers key regions including North America, Europe, Asia Pacific Middle East and Africa and South America. The North America with a focus on the U.S., Canada, and Mexico; Europe, highlighting major countries like the U.K., Germany, France, and Italy, along with other nations in the region; Asia-Pacific, covering India, China, Japan, South Korea, and Australia, among others; South America, with emphasis on Colombia, Brazil, and Argentina; and the Middle East & Africa, which includes Saudi Arabia, the U.A.E., South Africa, and other countries. This comprehensive regional breakdown helps identify unique market trends and growth opportunities specific to each area.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/parp-inhibitors-market?rk

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the PARP Inhibitors market?

➠ Who are the leading manufacturers in the global PARP Inhibitors industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global PARP Inhibitors industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the PARP Inhibitors market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Browse More Reports: https://www.datamintelligence.com/research-report/parp-inhibitors-market?rk

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.